355 related articles for article (PubMed ID: 30377936)
41. Diagnostic value of
Zhu AH; Hou XY; Tian S; Zhang WF
Sci Rep; 2022 Jan; 12(1):587. PubMed ID: 35022440
[TBL] [Abstract][Full Text] [Related]
42. Clinico-radio-pathologic features of a solitary solid renal mass at MDCT examination.
Kim EY; Park BK; Kim CK; Lee HM
Acta Radiol; 2010 Dec; 51(10):1143-8. PubMed ID: 20849320
[TBL] [Abstract][Full Text] [Related]
43. Diagnosis of complex renal cystic masses and solid renal lesions using PET imaging: comparison of 11C-acetate and 18F-FDG PET imaging.
Oyama N; Ito H; Takahara N; Miwa Y; Akino H; Kudo T; Okazawa H; Fujibayashi Y; Komatsu K; Tsukahara K; Yokoyama O
Clin Nucl Med; 2014 Mar; 39(3):e208-14. PubMed ID: 24217534
[TBL] [Abstract][Full Text] [Related]
44. Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma.
Kang DE; White RL; Zuger JH; Sasser HC; Teigland CM
J Urol; 2004 May; 171(5):1806-9. PubMed ID: 15076281
[TBL] [Abstract][Full Text] [Related]
45. Diagnostic performance of 18F-FDG PET or PET/CT in restaging renal cell carcinoma: a systematic review and meta-analysis.
Ma H; Shen G; Liu B; Yang Y; Ren P; Kuang A
Nucl Med Commun; 2017 Feb; 38(2):156-163. PubMed ID: 27824726
[TBL] [Abstract][Full Text] [Related]
46. Utility of
Siva S; Callahan J; Pryor D; Martin J; Lawrentschuk N; Hofman MS
J Med Imaging Radiat Oncol; 2017 Jun; 61(3):372-378. PubMed ID: 28116853
[TBL] [Abstract][Full Text] [Related]
47. Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents.
Hwang SH; Cho A; Yun M; Choi YD; Rha SY; Kang WJ
Clin Nucl Med; 2017 May; 42(5):e235-e241. PubMed ID: 28288043
[TBL] [Abstract][Full Text] [Related]
48. 18F-FDG-PET/CT in potentially advanced renal cell carcinoma: a role in treatment decisions and prognosis estimation.
Ferda J; Ferdova E; Hora M; Hes O; Finek J; Topolcan O; Kreuzberg B
Anticancer Res; 2013 Jun; 33(6):2665-72. PubMed ID: 23749925
[TBL] [Abstract][Full Text] [Related]
49. Preoperative evaluation of renal cell carcinoma by using 18F-FDG PET/CT.
Takahashi M; Kume H; Koyama K; Nakagawa T; Fujimura T; Morikawa T; Fukayama M; Homma Y; Ohtomo K; Momose T
Clin Nucl Med; 2015 Dec; 40(12):936-40. PubMed ID: 26164183
[TBL] [Abstract][Full Text] [Related]
50. Renal cell carcinoma in patients with acquired cystic disease of the kidney: assessment using a combination of T2-weighted, diffusion-weighted, and chemical-shift MRI without the use of contrast material.
Akita H; Jinzaki M; Akita A; Mikami S; Oya M; Kuribayashi S
J Magn Reson Imaging; 2014 Apr; 39(4):924-30. PubMed ID: 24123320
[TBL] [Abstract][Full Text] [Related]
51. Differentiating renal pelvic cancer from renal cell carcinoma with 18-fluorodeoxyglucose positron emission tomography-computed tomography.
Dursun M; Ozbek E; Otunctemur A; Besiroglu H
J Cancer Res Ther; 2021; 17(4):901-905. PubMed ID: 34528539
[TBL] [Abstract][Full Text] [Related]
52. Pyrexia of unknown origin as clinical presentation of Renal Cell Carcinoma: Role of F18-FDG PET/CT.
Asghar N; Hassan A
J Pak Med Assoc; 2020 Feb; 70(2):371. PubMed ID: 32063640
[TBL] [Abstract][Full Text] [Related]
53. Intense Choline Activity in Renal Cell Carcinoma Without Obvious 18F-FDG Uptake.
Xia X; Hu F; Qin C; Liu F; Lan X
Clin Nucl Med; 2019 Jan; 44(1):38-39. PubMed ID: 30371589
[TBL] [Abstract][Full Text] [Related]
54. Enhanced MRI and 18F-FDG PET/CT Findings of Preoperative Primary Renal Collecting Duct Carcinoma.
Ge J; Zuo C; Guan Y; Liang Z
Clin Nucl Med; 2016 Dec; 41(12):998-999. PubMed ID: 27775947
[TBL] [Abstract][Full Text] [Related]
55. The potential clinical value of FDG-PET for recurrent renal cell carcinoma.
Nakatani K; Nakamoto Y; Saga T; Higashi T; Togashi K
Eur J Radiol; 2011 Jul; 79(1):29-35. PubMed ID: 20015602
[TBL] [Abstract][Full Text] [Related]
56. Assessment of the diagnostic performance of (18)F-FDG-PET/CT for detection and characterization of solid renal malignancies.
Nakhoda Z; Torigian DA; Saboury B; Hofheinz F; Alavi A
Hell J Nucl Med; 2013; 16(1):19-24. PubMed ID: 23529389
[TBL] [Abstract][Full Text] [Related]
57. Diagnostic value of integrated PET/MRI for detection and localization of prostate cancer: Comparative study of multiparametric MRI and PET/CT.
Lee MS; Cho JY; Kim SY; Cheon GJ; Moon MH; Oh S; Lee J; Lee S; Woo S; Kim SH
J Magn Reson Imaging; 2017 Feb; 45(2):597-609. PubMed ID: 27586519
[TBL] [Abstract][Full Text] [Related]
58. FDG PET/CT as a survival prognostic factor in patients with advanced renal cell carcinoma.
Pankowska V; Malkowski B; Wedrowski M; Wedrowska E; Roszkowski K
Clin Exp Med; 2019 Feb; 19(1):143-148. PubMed ID: 30488140
[TBL] [Abstract][Full Text] [Related]
59. Role of contrast-enhanced 18F-FDG PET/CT imaging in the diagnosis and staging of renal tumors.
Gündoğan C; Çermik TF; Erkan E; Yardimci AH; Behzatoğlu K; Tatar G; Okçu O; Toktaş MG
Nucl Med Commun; 2018 Dec; 39(12):1174-1182. PubMed ID: 30234688
[TBL] [Abstract][Full Text] [Related]
60. Role of FDG PET-CT in recurrent renal cell carcinoma.
Kumar R; Shandal V; Shamim SA; Jeph S; Singh H; Malhotra A
Nucl Med Commun; 2010 Oct; 31(10):844-50. PubMed ID: 20661166
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
